Text size: A A A

Today, vitreomacular traction (VMT) and macular hole are most commonly diagnosed through optical coherence tomography (OCT)

  • VMT 12
    VMT12
    Vitreomacular (VMT) OCT scan
  • Macular hole12
    Macular hole12
    Macular hole OCT scan
  • Earlier and more reliable diagnosis of vitreomacular traction (VMT) and macular hole are now possible due to advances in OCT imaging8,9,15,25

    In the past, vitreomacular traction (VMT) was difficult to diagnose, as visual symptoms can vary and are mostly unspecific.8,25,26

Once your patient has been diagnosed with vitreomacular traction (VMT), there are three available options:

Watch and wait

"Watch and wait" has previously been the most common option for patients with vitreomacular traction (VMT)

The prolonged process of monitoring patients until visual symptoms worsen can lead to disease progression, complications, and in some cases, serious irreversible damage.8,27

In addition to physical symptoms, "watch and wait" can also have a negative impact on quality of life.16,17

JETREA® (ocriplasmin), a one-time intravitreal injection, has been shown to provide early resolution of vitreomacular traction (VMT), including when associated with macular hole of diameter ≤400 µm1

Until recently, the only available action to resolve vitreomacular traction (VMT), including macular hole, was vitrectomy

Vitrectomy is a surgical procedure performed when symptoms of vitreomacular traction (VMT), including macular hole, worsen. The procedure involves full or partial removal of the vitreous gel of the eye and the careful peeling of retinal membranes in some cases.10

Vitrectomy

Vitrectomy: Benefits and risks

Vitrectomy is generally reserved for more advanced stages of macular hole, when benefits are deemed to outweigh risks.18 In nonrandomized studies, the anatomic success rate of vitrectomy has been shown to range from approximately 80% to 100%.18 Among the more commonly occurring complications of vitrectomy are: cataract, retinal tear, retinal detachment, and visual field loss.18

Watch and wait
Watch and wait

"Watch and wait" has previously been the most common option for patients with vitreomacular traction (VMT)

The prolonged process of monitoring patients until visual symptoms worsen can lead to disease progression, complications, and in some cases, serious irreversible damage.8,27

In addition to physical symptoms, "watch and wait" can also have a negative impact on quality of life.16,17

JETREA®

JETREA® (ocriplasmin), a one-time intravitreal injection, has been shown to provide early resolution of vitreomacular traction (VMT), including when associated with macular hole of diameter ≤400 µm1

Vitrectomy
Vitrectomy

Until recently, the only available action to resolve vitreomacular traction (VMT), including macular hole, was vitrectomy

Vitrectomy is a surgical procedure performed when symptoms of vitreomacular traction (VMT), including macular hole, worsen. The procedure involves full or partial removal of the vitreous gel of the eye and the careful peeling of retinal membranes in some cases.10

Vitrectomy: Benefits and risks

Vitrectomy is generally reserved for more advanced stages of macular hole, when benefits are deemed to outweigh risks.18 In nonrandomized studies, the anatomic success rate of vitrectomy has been shown to range from approximately 80% to 100%.18 Among the more commonly occurring complications of vitrectomy are: cataract, retinal tear, retinal detachment, and visual field loss.18

Cataract formation
Cataract formation
Retinal tear
Retinal tears
Retinal detachment
Retinal detachment
Watch and wait

"Watch and wait" has previously been the most common option for patients with vitreomacular traction (VMT)

The prolonged process of monitoring patients until visual symptoms worsen can lead to disease progression, complications, and in some cases, serious irreversible damage.8,27

In addition to physical symptoms, “watch and wait” can also have a negative impact on quality of life.16,17

Next: Efficacy

Take action with JETREA® (ocriplasmin) Intravitreal (IVT) Injection

JETREA® Cross eye JETREA® Cross eye JETREA® Cross eye

A one-time injection of JETREA® has been shown to provide early resolution of vitreomacular traction, including when associated with macular hole of diameter ≤400 µm.1

LEARN MORE

Learn about the impact of vitreomacular traction and macular hole on your patients

Metamorphopsia from a patient perspective Metamorphopsia from a patient perspective Metamorphopsia from a patient perspective

Vitreomacular traction and macular hole often result in visual impairment, particularly central vision loss.8,9

LEARN MORE

See the JETREA® difference in your practice with the Impact Calculator™

Impact Calculator® Impact Calculator® Impact Calculator®

Calculate how many patients with vitreomacular traction you can potentially treat in 1 year with the one-time injection of JETREA®.1

LEARN MORE

Important Safety Information

Indications: JETREA® is indicated in adults for the treatment of vitreomacular traction (VMT), including when associated with macular hole of diameter less than or equal to 400 microns.

Dosage: JETREA® must be prepared and administered by a qualified ophthalmologist experienced in intravitreal injections. The recommended dose is 0.125 mg (0.1 mL of the diluted solution) administered by intravitreal injection to the affected eye once as a single dose.

Contraindications: JETREA® is contraindicated for use with patients who are hypersensitive to ocriplasmin or to any of the excipients in JETREA® (mannitol, citric acid, sodium hydroxide and water), or with patients who have active or suspected ocular or periocular infections.

Warnings and Precautions: Post-Injection Monitoring: Intravitreal injections have been associated with intraocular inflammation/infection, intraocular haemorrhage and increased intraocular pressure (IOP). Proper aseptic injection techniques must always be used. Following the intravitreal injection, patients should be monitored for any side effects such as (but not limited to) intraocular inflammation/infection and elevation in IOP. Other Warnings and Precautions: Administration of JETREA® to both eyes concurrently has not been studied, and is not recommended. Repeated administration of JETREA® in the same eye has not been studied, and is not recommended. There are no clinical data on the concomitant use of ocriplasmin with VEGF-inhibitors. JETREA® has not been studied in patients with large diameter macular holes (>400 microns), high myopia (>8 dioptre spherical correction or axial length >28 mm), aphakia, history of rhegmatogenous retinal detachment, lens zonule instability, recent ocular surgery or intraocular injection (including laser therapy), proliferative diabetic retinopathy, ischaemic retinopathies, retinal vein occlusions, exudative age-related macular degeneration (AMD) and vitreous haemorrhage; treatment is not recommended in these patients. The potential for lens subluxation or phacodonesis cannot be ruled out. There is limited experience in patients with non-proliferative diabetic retinopathy or in patients with a history of uveitis or significant eye trauma; caution should be exercised when treating such patients. The effect of ocriplasmin (particularly in inducing resolution of vitreomacular adhesion (VMA) or causing total posterior vitreous detachment (PVD) is reduced in subjects with an epiretinal membrane (ERM) or a diameter of VMA >1500 microns. Due to a potential increase in tractional forces, there is a risk of occurrence of new or enlarged macular holes. There is a risk for a significant, but transient loss of visual acuity during the first week after the injection; patients should be monitored appropriately.

Interactions: No formal interaction studies have been conducted.

Undesirable Effects: In the JETREA® clinical studies, all adverse reactions were ocular. Most of the adverse reactions occurred within the first week after the injection. The majority of these reactions were non-serious, mild in intensity and resolved within 2 to 3 weeks. The incidence of serious adverse reactions that occurred in all clinical studies was 2.2% in JETREA® treated patients and 2.4% in placebo-controlled patients. Very common (≥1/10) adverse reactions are: vitreous floaters, eye pain, and conjunctival haemorrhage. Common (≥1/100 to <1/10) adverse reactions are: visual acuity reduced, visual impairment, vision blurred, retinal haemorrhage, vitreous haemorrhage, retinal tear, retinal detachment, intraocular pressure increased,macular hole, macular degeneration, retinal degeneration, macular oedema, retinal oedema, retinal pigment epitheliopathy, metamorphopsia, vitreous adhesions, conjunctival oedema, eyelid oedema, vitritis, anterior chamber cell, anterior chamber flare, iritis, photopsia, conjunctival hyperaemia, ocular hyperaemia, vitreous detachment, retinogram abnormal, eye irritation, dry eye, foreign body sensation in eyes, eye pruritus, ocular discomfort, photophobia, and chromatopsia. Uncommon (≥1/1,000 to <1/100) are: transient blindness, lens subluxation, scotoma, visual field defect, diplopia, hyphaema, miosis, pupils unequal, corneal abrasion, anterior chamber inflammation, eye inflammation, and conjunctival irritation.

Click here to review the JETREA® Summary of Product Characteristics.